Enhancement of 131I-mediated cytotoxicity by caffeine

Gynecologic Oncology

Volumn 65, Issue 2, 1997, Pages 253-257

  Anderson, Lisa L ^a,c   Lau, Ching C ^a,d   Gracely, Edward J ^c   Berkowitz, Ross S ^a   Kassis, Amin I ^b  

^a Department of Obstetrics and Gynecology   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; IODINE 131; RADIOACTIVE IODINE;

ANIMAL CELL; ARTICLE; CANCER RADIOTHERAPY; CHO CELL; CYTOTOXICITY; DNA DAMAGE; ISOTOPE LABELING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; ULTRAVIOLET IRRADIATION; ANIMAL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HAMSTER; HUMAN; RADIATION EXPOSURE;

ANIMALS; CAFFEINE; CELL SURVIVAL; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IODINE RADIOISOTOPES;

EID: 0031128580     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4644     Document Type: Article

References (44)

1. Neijt J P, ten Bokkel Huinink W W, van der Burg M EL, van Oosterom A T, Vriesendorp R, Kooyman C D, van Lindert A CM, Hamerlynk J VTH, van Lent M, van Houwelingen J C, Pinedo H M. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet. 2:1984;594-600.
2. Ozols R F, Young R C. Chemotherapy of ovarian cancer. Semin Oncol. 11:1984;251-263.
3. Seltzer V, Vogl S, Kaplan B. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy includingcis. Gynecol Oncol. 21:1985;167-176.
4. Mulder P OM, Willemse P H, Aalders J G, deVries E GE, Sleijfer D T, Sibinga C T, Mulder N H. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol. 25:1989;645-649.
5. Byfield J E, Murnane J, Ward J F, Calabro-Jones P, Lynch M, Kulhanian F. Mice, men, mustard, and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents. Br J Cancer. 43:1981;669-683.
6. Finkler N J, Muto M G, Kassis A I, Weadock K, Tumeh S S, Zurawski V R Jr, Knapp R C. Intraperitoneal radiolabeled OC125 in patients with advanced ovarian cancer. Gynecol Oncol. 34:1989;339-344.
7. Muto M G, Finkler N J, Kassis A I, Howes A E, Anderson L L, Lau C C, Zurawski V R Jr, Weadock K, Tumeh S S, Lavin P, Knapp R C. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol. 45:1992;265-272.
8. Haisma H J, Hilgers J, Zurawski V R Jr. Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method. J Nucl Med. 27:1986;1890-1895.
9. C, C, Lau, M, JB, Marques, J, CA, Alves-da Corte, G, NMP, Dos Santos, I, CR, Lencastre, 1989, A rapid assay for detecting clastogenic agents, in Public Health and Protection of the Population - Proceedings of the 1st International Congress on Public Health and Sanitary Protection of the Population, 293, 300, Excerpta Medica, Amsterdam.
10. Epenetos A A, Munro A J, Stewart S, Rampling R, Lambert H E, McKenzie C G, Soutter P, Rahemtulla A, Hooker G, Sivolapenko G B, Snook D, Courtenay-Luck N, Dhokia B, Krausz T, Taylor-Papadimitriou J, Durbin H, Bodmer W F. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol. 5:1987;1890-1899.
11. Webb M J, Snyder J A Jr, Williams T J, Decker D G. Second-look laparotomy in ovarian cancer. Gynecol Oncol. 14:1982;285-293.
12. Smirz L R, Stehman F B, Ulbright T M, Sutton G P, Ehrlich C E. Second-look laparotomy after chemotherapy in the management of ovarian malignancy. Am J Obstet Gynecol. 152:1985;661-668.
13. Podratz K C, Malkasian G D Jr, Wieand H S, Cha S S, Lee R A, Stanhope C R, Williams T J. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol. 29:1988;274-282.
14. Hacker N F, Berek J S, Burnison C M, Heintz A PM, Juillard G JF, Lagasse L D. Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet Gynecol. 65:1985;60-66.
15. Schray M F, Martinez A, Howes A E, Ballon S C, Podratz K C, Sikic B I, Malkasian G D. Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and reoperation. Gynecol Oncol. 24:1986;68-80.
16. Shelley W E, Starreveld A A, Carmichael J A, O'Connell G, Roy M, Swenerton K. Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomy. Obstet Gynecol. 71:1988;327-332.
17. Rosenshein N B, Leichner P K, Vogelsang G. Radiocolloids in the treatment of ovarian cancer. Obstet Gynecol Surv. 34:1979;708-720.
18. Bakri Y N, Given F T Jr, Peeples W J, Frazier A B. Complications from intraperitoneal radioactive phosphorus in ovarian malignancies. Gynecol Oncol. 21:1985;294-299.
19. Soper J T, Wilkinson R H Jr, Bandy L C, Clarke-Pearson D L, Creasman W T. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol. 156:1987;1153-1158.
20. 131. Br J Cancer. 58:1988;658-662.
21. Chatal J-F, Saccavini J-C, Gestin J-F, Thédrez P, Curtet C, Kremer M, Guerreau D, Nolibé D, Fumoleau P, Guillard Y. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res. 49:1989;3087-3094.
22. Stewart J SW, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G, Taylor Papadimitriou J, Rowlinson G, Sullivan M, Lambert H E, Coulter C, Mason W P, Soutter W P, Epenetos A A. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol. 8:1990;1941-1950.
23. Busse P M, Bose S K, Jones R W, Tolmach L J. The action of caffeine on X-irradiated HeLa cells. II. Synergistic lethality. Radiat Res. 71:1977;666-677.
24. Waldren C A, Rasko I. Caffeine enhancement of X-ray killing in cultured human and rodent cells. Radiat Res. 73:1978;95-110.
25. 2. Radiat Res. 76:1978;292-307.
26. Tolmach L J, Busse P M. The action of caffeine on X-irradiated HeLa cells. IV. Progression delays and enhanced cell killing at high caffeine concentrations. Radiat Res. 82:1980;374-392.
27. Hartwell L H, Weinert T A. Checkpoints: controls that ensure the order of cell cycle events. Science. 246:1989;629-634.
28. O'Connor P M, Kohn K W. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin Cancer Biol. 3:1992;409-416.
29. Murray A W. Creative blocks: cell-cycle checkpoints and feedback controls. Nature. 359:1992;599-604.
30. Kuerbitz S J, Plunkett B S, Walsh W V, Kastan M B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 89:1992;7491-7495.
31. Hartwell L H, Kastan M B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
32. Smith M L, Fornace A J Jr. Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol. 7:1995;69-75.
33. 2. Radiat Res. 129:1992;224-227.
34. Lau C C, Pardee A B. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA. 79:1982;2942-2946.
35. Musk S RR. Reduction of radiation-induced cell cycle blocks by caffeine does not necessarily lead to increased cell killing. Radiat Res. 125:1991;262-266.
36. Slichenmyer W J, Nelson W G, Slebos R J, Kastan M B. Loss of ap53. Cancer Res. 53:1993;4164-4168.
37. Snyder M H, Kimler B F, Leeper D B. The effect of caffeine on radiation-induced division delay. Int J Radiat Biol. 32:1977;281-284.
38. Oleinick N L, Brewer E N, Rustad R C. The reduction of radiation-induced mitotic delay by caffeine: a test of the cyclic AMP hypothesis. Int J Radiat Biol. 33:1978;69-73.
39. 2. Radiother Oncol. 23:1992;150-159.
40. Dalvi R R. Acute and chronic toxicity of caffeine: a review. Vet Hum Toxicol. 28:1986;144-150.
41. Ward A, Clissold S P. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 34:1987;50-97.
42. Dezube B J, Eder J P, Pardee A B. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Cancer Res. 50:1990;6806-6810.
43. Song C W, Hasegawa T, Kwon H C, Lyons J C, Levitt S H. Increase in tumour oxygenation and radiosensitivity caused by pentoxifylline. Radiat Res. 130:1992;205-210.
44. Honess D J, Dennis I F, Bleehen N M. Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. Radiother Oncol. 28:1993;208-218.